OncoMatch/Clinical Trials/NCT05093335

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

Is NCT05093335 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies [68Ga]-Pentixafor for non-hodgkin lymphoma.

Early Phase 1RecruitingMemorial Sloan Kettering Cancer CenterNCT05093335Data as of May 2026

Treatment: [68Ga]-Pentixafor — The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Multiple Myeloma

Lab requirements

Kidney function

No history of renal functional disorders (chronic kidney disease with eGFR<30)

History of renal functional disorders (chronic kidney disease with eGFR<30) [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Memorial Sloan Kettering Cancer Center · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify